New protocol from Japan enables high-affinity monoclonal antibody production from single B cells in 6 days.
Cost-effective and works across antibody types, including for SARS-CoV-2 spike protein.
My note: Would like to see study on this drug with endpoints like time to recovery, severity of symptoms, long-term follow-up for post-acute symptoms. Not holding my breath. This is, after all, Giliad, the maker of remdesivir. Still, potential early treatment option here:
465 adults received either obeldesivir or a placebo for 5 days. The results showed that those on obeldesivir had a 0% hospitalization rate and lower mortality compared to 0.5% in the placebo group.
Patients taking obeldesivir also experienced quicker symptom relief and greater reductions in the virus levels. Overall, the drug was found to be generally safe and well-tolerated.
